2 weeks Ago By ABMN Staff
Norges Bank purchased a new stake in shares of Organogenesis Holdings Inc. ( NASDAQ:ORGO – Free Report ) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 482,200 shares of the company’s stock, valued at approximately $1,543,000.
A number of other hedge funds have also modified their holdings of ORGO. Assenagon Asset Management S.A.
boosted its position in Organogenesis by 54.0% during the fourth quarter. Assenagon Asset Management S.
A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after purchasing an additional 1,035,120 shares during the last quarter. State Street Corp raised its stake in shares of Organogenesis by 0.
6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after purchasing an additional 9,090 shares in the last quarter. Charles Schwab Investment Management Inc.
lifted its holdings in shares of Organogenesis by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc.
now owns 948,451 shares of the company’s stock valued at $2,713,000 after buying an additional 23,675 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Organogenesis by 35.5% in the 4th quarter.
Bank of New York Mellon Corp now owns 418,820 shares of the company’s stock valued at $1,340,000 after buying an additional 109,762 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Organogenesis by 36.
4% in the fourth quarter. JPMorgan Chase & Co. now owns 280,997 shares of the company’s stock worth $899,000 after buying an additional 75,054 shares during the last quarter.
49.57% of the stock is owned by institutional investors and hedge funds. Analyst Ratings Changes Separately, Morgan Stanley lifted their target price on shares of Organogenesis from $4.
00 to $6.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Organogenesis Trading Up 13.
6 % Organogenesis stock opened at $4.26 on Friday. Organogenesis Holdings Inc.
has a one year low of $2.17 and a one year high of $6.71.
The company’s fifty day moving average price is $4.32 and its two-hundred day moving average price is $3.68.
The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.
74. The company has a market capitalization of $540.29 million, a price-to-earnings ratio of -71.
00 and a beta of 1.79. Insider Transactions at Organogenesis In other news, Director Michael Joseph Driscoll sold 25,000 shares of the business’s stock in a transaction on Tuesday, March 4th.
The shares were sold at an average price of $5.10, for a total value of $127,500.00.
Following the completion of the sale, the director now directly owns 166,879 shares in the company, valued at approximately $851,082.90. The trade was a 13.
03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . 36.
90% of the stock is currently owned by corporate insiders. Organogenesis Profile ( Free Report ) Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Featured Stories Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. ( NASDAQ:ORGO – Free Report ).
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter ..
